Funding terms in text
| Party or condition | Announced terms |
|---|---|
| Blackstone-managed funds | Pay up to $1.5 billion of development costs through 2028. |
| Pfizer | Retains ownership, operational control and program decisions. |
| Potential payments to Blackstone | Milestone-based; subject to U.S. approval of monthly injectable berobenatide alone for chronic weight management and achievement of commercial sales milestones. |
Conceptual flow diagram. No annual funding schedule, total development budget or investment return is implied.
Pfizer (NYSE: PFE) has found a partner to help pay for an experimental monthly weight-loss injection. Funds managed by Blackstone will cover up to $1.5 billion of berobenatide development costs through 2028. [1]
The November 11 agreement lets Pfizer share the research bill while keeping the drug and decisions about its development. [1]
A monthly injection still has to earn its place
Berobenatide is being developed to help people manage obesity over time. In June, Pfizer reported earlier trials testing doses and how patients could move from weekly injections to a monthly maintenance dose. Those studies helped choose doses for the larger Phase 3 trials intended to support approval. [2]
The practical appeal is fewer injections. But convenience only becomes valuable if the medicine also delivers useful weight loss with acceptable safety. Pfizer's earlier findings support further testing; they do not establish that a monthly product will win approval or succeed commercially. [2]
The company's current development calendar includes a monthly weight-management study that began in June, a study of switching from approved weekly injections, and work on obesity-related knee arthritis and sleep apnea. That breadth gives Pfizer several questions to answer about where the drug might fit, beyond showing that weight falls. [4]
Research competes with the rest of the business
Pfizer is funding that work while rebuilding growth across a large medicine portfolio. Its November 3 results showed third-quarter revenue of $16.6 billion, roughly unchanged from a year earlier before currency effects. Excluding its COVID vaccine and antiviral treatment, revenue grew 7% on that same basis. [3]
The research bill was growing faster. Reported research and development expense reached about $3.0 billion for the quarter, up 18%. That figure covers Pfizer's research broadly, rather than this one drug. The company also expects generic and similar competing medicines to reduce 2026 revenue by about $1.1 billion. New products have to offset erosion elsewhere. [3]
“maintain the financial capacity and flexibility to invest in our broader pipeline”
The partner gets a conditional claim on success
Blackstone acquires no ownership or rights in berobenatide. Instead, it can earn payments tied to U.S. approval of the monthly injection used alone for weight management and commercial sales milestones. Earned payments would be spread over several years. [1]
The market connection Pfizer gains help with today's trial costs in exchange for potential payments later. The funding makes the program easier to finance; the ongoing trials must still deliver a medicine worth selling.